drugset / Trial / NCT03839459
Denosumab for Smoldering Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
This study will assess the safety and tolerability of denosumab in smoldering multiple myeloma subjects as well to see if denosumab can reduce subjects' risk of getting multiple myeloma.
Timeline
- Start
- 2019-04-19
- Primary completion
- 2022-09-16
- Completion
- 2025-01-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Denosumab | Monoclonal antibody | 120 mg | Subcutaneous |